Health Canada authorizes Eli Lilly's oral GLP-1 weight-loss pill Foundayo
Just the facts

Health Canada authorizes Eli Lilly's oral GLP-1 weight-loss pill Foundayo

Summary

Health Canada approved Eli Lilly’s daily oral GLP-1 medication Foundayo for obesity and weight-related health issues, with availability expected in pharmacies in January.

Health Canada granted approval for Eli Lilly’s oral GLP-1 medication Foundayo, a daily pill indicated for adults with obesity and for those who are overweight with at least one related condition such as high blood pressure or sleep apnea. The approval also covers treatment of type 2 diabetes.

Foundayo contains the non-peptide GLP-1 receptor agonist orforglipron, which can be absorbed orally because it is a smaller molecule than peptide-based drugs such as semaglutide and tirzepatide. Dr. Ehud Ur, an endocrinologist in Vancouver, said the pill “seems to be just as good as if not better” for weight loss compared with existing injectable GLP-1 therapies.

The most common side effects reported for GLP-1 agents, whether injectable or oral, are gastrointestinal issues such as nausea or vomiting. Dr. Ur noted that his decision to prescribe Foundayo will depend on individual patients and on forthcoming trial data regarding any cardiovascular benefits.

Eli Lilly spokesperson Ethan Pigott said the company expects the medication to reach Canadian pharmacies in January. A second oral GLP-1 weight-loss option, Novo Nordisk’s Wegovy pill, is awaiting Health Canada approval. Novo Nordisk spokesperson Kate Hanna explained that the Wegovy pill uses salcaprozate sodium (SNAC) to protect the peptide semaglutide from digestive enzymes, allowing it to be absorbed after ingestion.

Keep reading — for free

Create a free account to follow the news. No card required.